{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:10:20Z","timestamp":1762431020264,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T00:00:00Z","timestamp":1438819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00535-015-1106-8","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T05:58:54Z","timestamp":1438754334000},"page":"260-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing"],"prefix":"10.1007","volume":"51","author":[{"given":"Yoshihito","family":"Uchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kouyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie","family":"Inao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,6]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7883\/yoken.JJID.2002.69","volume":"55","author":"M Higuch","year":"2002","unstructured":"Higuch M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis. 2002;55:69\u201377.","journal-title":"Jpn J Infect Dis"},{"key":"1106_CR2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1872-034X.2007.00119.x","volume":"37","author":"I Ikai","year":"2007","unstructured":"Ikai I, Arii S, Okazaki M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676\u201391.","journal-title":"Hepatol Res"},{"issue":"Suppl19","key":"1106_CR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00535-008-2251-0","volume":"44","author":"T Umemura","year":"2009","unstructured":"Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl19):102\u20137.","journal-title":"J Gastroenterol"},{"key":"1106_CR4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"1106_CR5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","volume":"56","author":"H Kumada","year":"2012","unstructured":"Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56:78\u201384.","journal-title":"J Hepatol"},{"key":"1106_CR6","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1111\/j.1365-2893.2011.01528.x","volume":"19","author":"N Hayashi","year":"2012","unstructured":"Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19:e134\u201342.","journal-title":"J Viral Hepat"},{"key":"1106_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jhep.2013.03.020","volume":"59","author":"N Furusyo","year":"2013","unstructured":"Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013;59:205\u201312.","journal-title":"J Hepatol"},{"key":"1106_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00535-012-0714-9","volume":"48","author":"K Chayama","year":"2013","unstructured":"Chayama K, Hayes CN, Ohishi W, et al. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1\u201312.","journal-title":"J Gastroenterol"},{"key":"1106_CR9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00535-013-0889-8","volume":"49","author":"K Sugawara","year":"2014","unstructured":"Sugawara K, Inao M, Nakayama N, et al. Telaprevir-induced, but not PEGylated interferon-associated, retinopathy as a noteworthy. J Gastroenterol. 2014;49:363\u20138.","journal-title":"J Gastroenterol"},{"key":"1106_CR10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2014.04.004","volume":"61","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014;61:218\u201327.","journal-title":"J Hepatol"},{"key":"1106_CR11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","volume":"49","author":"N Izumi","year":"2014","unstructured":"Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: The CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941\u201353.","journal-title":"J Gastroenterol"},{"key":"1106_CR12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/hepr.12375","volume":"45","author":"H Kumada","year":"2015","unstructured":"Kumada H, Hayashi N, Izumi N, et al. Simeprevir (TMC435) once daily with peginterferon-\u03b1-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res. 2015;45:501\u201313.","journal-title":"Hepatol Res"},{"key":"1106_CR13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00535-014-0979-2","volume":"50","author":"N Hayashi","year":"2015","unstructured":"Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238\u201348.","journal-title":"J Gastroenterol"},{"key":"1106_CR14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","volume":"58","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655\u201362.","journal-title":"J Hepatol"},{"key":"1106_CR15","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"1106_CR16","author":"K Sugawara","year":"2015","unstructured":"Sugawara K, Koushima Y, Inao M, et al. Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b HCV infection according to an algorithm based on the drug adherence, IL28B gene allele and viral response: the AG and RGT Trial. Hepatol Res. 2015;. doi: 10.1111\/hepr.12475 (In press).","journal-title":"Hepatol Res"},{"key":"1106_CR17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","volume":"58","author":"Y Karino","year":"2013","unstructured":"Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646\u201354.","journal-title":"J Hepatol"},{"key":"1106_CR18","doi-asserted-by":"crossref","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.","journal-title":"PLoS One"},{"key":"1106_CR19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000086064","volume":"48","author":"N Akuta","year":"2005","unstructured":"Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372\u201380.","journal-title":"Intervirology"},{"key":"1106_CR20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to PEGylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nature Gent. 2009;41:1105\u20139.","journal-title":"Nature Gent"},{"key":"1106_CR21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54:352\u20134.","journal-title":"J Clin Virol"},{"key":"1106_CR22","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1111\/hepr.12316","volume":"44","author":"M Miura","year":"2014","unstructured":"Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variant resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360\u20137.","journal-title":"Hepatol Res"},{"key":"1106_CR23","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641\u201350.","journal-title":"Antimicrob Agents Chemother"},{"key":"1106_CR24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00535-010-0293-6","volume":"46","author":"M Tateyama","year":"2011","unstructured":"Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92\u2013100.","journal-title":"J Gastroenterol"},{"key":"1106_CR25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","volume":"58","author":"Y Asahina","year":"2013","unstructured":"Asahina Y, Tsuchiya K, Nishimura T, et al. \u03b1-fetoprotein levels after interferon therapy and risk of hepatocellular carcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253\u201362.","journal-title":"Hepatology"},{"key":"1106_CR26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/2053","volume":"4","author":"K Moriya","year":"1998","unstructured":"Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065\u20137.","journal-title":"Nat Med"},{"key":"1106_CR27","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/hep.25949","volume":"46","author":"N Akuta","year":"2012","unstructured":"Akuta N, Suzuki F, Seko Y, et al. Complicated relationship of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;46:2134\u201341.","journal-title":"Hepatology"},{"key":"1106_CR28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2010.03.022","volume":"53","author":"H Abe","year":"2010","unstructured":"Abe H, Ochi H, Maekawa T, et al. Common variation of IL28B affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010;53:439\u201343.","journal-title":"J Hepatol"},{"key":"1106_CR29","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s00535-012-0531-1","volume":"47","author":"M Kobayashi","year":"2012","unstructured":"Kobayashi M, Suzuki F, Akuta N, et al. Association of the polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596\u2013605.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1106-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-015-1106-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1106-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T21:53:25Z","timestamp":1748555605000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-015-1106-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1007\/s00535-015-1106-8","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2015,8,6]]}}}